Abcellera Biologics vs Enanta Pharmaceuticals
Abcellera Biologics is the larger business, with $75.1m of revenue in fiscal 2025 against $65.3m for Enanta Pharmaceuticals (1.2 times as much). Abcellera Biologics grew faster (160.6% against -3.4%). Enanta Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -125.4% against -194.9%. Abcellera Biologics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Abcellera BiologicsABCL, 2025 | Enanta PharmaceuticalsENTA, 2025 |
|---|---|---|
| Revenue | $75.1m | $65.3m |
| Revenue growth | 160.6% | -3.4% |
| Net income | −$146m | −$81.9m |
| Operating margin | -289.0% | -130.7% |
| Net margin | -194.9% | -125.4% |
| Return on equity | -14.5% | -84.6% |
| Free cash flow | −$174m | −$32.2m |
| Cash | $129m | $32.3m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 562 | 120 |
| Market value | $3.71bn | $305m |
| Price vs our value range | — | — |
| Moat score | 17 (Weak) | 17 (Weak) |
| Insider trades, 12 months | 9 buys, 0 sales | 0 buys, 9 sales |